Compositions and methods for inhibition of the JAK pathway
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
1. A compound of formula II
or a pharmaceutically acceptable salt thereof, wherein:
X is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;
R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl and substituted cycloalkyl;
ring A is phenyl;
Y is selected from the group consisting of a bond, —NR 7 —, —C(O)NR 7 —, —NR 7 C(O)—,
—NR 7 C(O)O—, —OC(O)NR 7 —, —NR 7 C(O)NR 7 —, oxygen and sulfur, where R 7 is independently hydrogen, alkyl or substituted alkyl;
alk is a bond or a straight or branched chain alkylene group, wherein when alk and Y each are a bond then R 1 is attached to ring A by a single covalent bond;
R 1 is selected from the group consisting of cyano, acylamino, aminoacyl, aryl, substituted aryl, carboxyl, carboxyl ester, carboxyl ester oxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, acyl, aminoacyloxy, and aminocarbonylamino; or
R 1 -alk-Y— is R 10 —C(O)—S-alk-C(O)—, wherein alk is as defined herein and R 10 is alkyl or substituted alkyl; or
R 1 -alk-Y— is R 11 R 12 NS(O) 2 —, wherein R 11 and R 12 independently are alkyl or substituted alkyl;
p is 0, 1, 2 or 3;
each R 2 independently is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryloxy, substituted aryloxy, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, nitro, and halo;
Z 1 , Z 2 , and Z 3 are carbon;
q is 1, 2 or 3;
each R 3 independently is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl or substituted cycloalkyl, halo, heterocyclic and substituted heterocyclic;
R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl and M + , wherein M + is a metal counterion selected from the group consisting of K + , Na + , Li + , or + N(R 6 ) 4 , wherein R 6 is hydrogen or alkyl, and the nitrogen of SO 2 NR 4 W is N − , a divalent counterion selected from the group consisting of Ca 2+ , Mg 2 +, and Ba 2+ , and the nitrogen of SO 2 NR 4 W is N − ;
W is selected from the group consisting of C 1 -C 3 alkylene, substituted C 1 -C 3 alkylene, C 2 -C 3 alkenylene and substituted C 2 -C 3 alkenylene wherein one or more of the carbon atoms have been replaced with a moiety selected from oxygen, sulfur, S(O), S(O) 2 , C(O), or NR 8 where R 8 is selected from the group consisting of hydrogen and alkyl or is a bond participating in a —N═C< site of unsaturation.
2. The compound of claim 1 having a formula IIA:
3. A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with an amount of a compound of claim 1 effective to inhibit an activity of the JAK kinase.
4. A method of inhibiting an activity of a JAK kinase, comprising contacting in vitro a JAK3 kinase with an amount of a compound of claim 1 effective to inhibit an activity of the JAK kinase.
5. A pharmaceutical formulation comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient, diluent, preservative, or stabilizer, or mixtures thereof.